Ardelyx, Inc. Reports Employment Inducement Grants
On December 16, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced employment inducement grants for 17 non-executive employees, totaling 271,735 stock options and 123,375 Restricted Stock Units (RSUs). The stock options have an exercise price of $1.96, aligning with the company's closing stock price on the grant date. Both stock options and RSUs will vest over four years. Ardelyx is dedicated to developing innovative treatments for unmet medical needs, with products like IBSRELA and ongoing clinical trials for other candidates.
- Granting of 271,735 stock options and 123,375 RSUs may enhance employee retention and motivation.
- Aligns compensation incentives with company performance through stock options.
- None.
WALTHAM, Mass., Dec. 23, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on December 16, 2022, the compensation committee of the company's board of directors granted 17 new non-executive employees options to purchase an aggregate of 271,735 shares of the company's common stock, and an aggregate of 123,375 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to
Each stock option vests over four years, with
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https://ardelyx.com/ and connect with us on Twitter @Ardelyx, LinkedIn and Facebook.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-inc-reports-employment-inducement-grants-301709815.html
SOURCE Ardelyx
FAQ
What was announced by Ardelyx on December 23, 2022?
What is the exercise price of the stock options granted by Ardelyx?
How long is the vesting period for the stock options and RSUs granted by Ardelyx?
What is the significance of the grants made by Ardelyx?